G1 Therapeutics Inc (NASDAQ:GTHX) was the target of a significant growth in short interest in December. As of December 29th, there was short interest totalling 697,343 shares, a growth of 29.0% from the December 15th total of 540,660 shares. Based on an average daily volume of 124,734 shares, the short-interest ratio is presently 5.6 days. Currently, 4.3% of the shares of the stock are short sold.
GTHX has been the subject of several analyst reports. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, BTIG Research initiated coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. G1 Therapeutics has an average rating of “Buy” and a consensus target price of $31.40.
In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark A. Velleca sold 7,500 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The disclosure for this sale can be found here. Insiders sold 542,156 shares of company stock valued at $10,761,689 over the last 90 days.
G1 Therapeutics (NASDAQ GTHX) opened at $23.04 on Friday. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67. The company has a market capitalization of $653.08 and a price-to-earnings ratio of -10.72.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.